PARD (PONIARD PHARMA)

Zecco.com
All Pro Portfolios with PARD

People owning PARD also tend to own:: ENERHALFLRNYXBIOFEKIFON

All Do-It-Yourself Portfolios with PARD
  • News For Selected Stock
  • Related stories on theStreet.com
  • videos related to etf's
  • No videos found
  •  
  • blogs related to etf's
  • No blogs found
  •  

Why I Love This Stock

By:rustus

Date:11 01 07

barrons recomend

Not yet rated
Rate now:

By:barrons2

Date:09 08 07

Buy - Price 6.07 on Sept. 5
by Cantor Fitzgerald
Poniard announced updated results from its Phase II trial of picoplatin in patients with small-cell lung cancer who relapsed within six months of first-line therapy....The one-year survival rate of 17.6% with single-agent picoplatin, reported for the first time, compares favorably with 9% and 15.2% one-year survival rates in two other clinical trials evaluating the combination of paclitaxel+carboplatin and topotecan+cisplatin, respectively....Poniard also notes that it is on track to reach its enrollment target in first-half '08, with a [new-drug application] possible in 2009 if results are positive. In our view, Poniard continues to execute its clinical development plan for picoplatin effectively and on schedule. Maintaining one-year price target of 12.

Not yet rated
Rate now:

By:Barrons

Date:05 26 07

From Barron's 5-21-07

"Poniard [has] announced that data from a Phase II trial for picoplatin as a second-line agent in small-cell lung cancer will be presented at [the American Society of Clinical Oncology conference in Chicago] on June 3. Recall that during an interim analysis from a single-arm Phase 2 trial in November 2006, picoplatin demonstrated a 27-week survival benefit in 72 evaluable patients. The [presentation] at ASCO will include results from all 77 patients enrolled and will demonstrate a survival benefit that, we believe, will exceed the 27-week benefit established during the interim analysis...Risks include limited safety data/efficacy data for picoplatin in metastatic colorectal cancer.... Maintain Buy rating and $11 price target."

Not yet rated
Rate now:

By:Kurt Anders

Date:05 06 07

Pharmaceutical company.

Not yet rated
Rate now:

By:Barrons

Date:05 05 07

A Director and Beneficial Owner of the company have recently purchased 134,725 shares or $853 ,000 worth of stock.

Not yet rated
Rate now:

By:Natalie Bell

Date:01 23 07

speculative idea

Not yet rated
Rate now:

Why I Hate This Stock

By:cdubl07

Date:03 18 08

I am mixed on this one because they are close to getting FDA approval for a new cancer drug but last summer they inflated their own stock price with company officers buying significant chunks of stock (my opinion). This could be profitable but I was suspect about the ethics and what else may be misleading.

Not yet rated
Rate now:

By:thazapis

Date:05 24 07

disappointing track record

Not yet rated
Rate now:
Add Your Comments  
Stock PARD
Allowed HTML tags: <a><b><i><img>
  Login to post your comments
Cramer's Take on Top-Searched St...

After a while, even investors get used to the bad news. Thursday started moderately low, a tempered response given all the recent bad news from retailers. But investo...

12.04.08 | 18:20 PM
Jim Cramer's Portfolios of the Week

Jim Cramer continues to find more reasons to be optimistic about the U.S. stock market. Recently, he has noticed that many new developments and changes are beginning to hap...

12.04.08 | 17:13 PM
Top Stocks With Insider Buying, ...

Part of the philosophy of Stockpickr is to follow in the footsteps of smart people. This could mean a few different things. First, it could mean piggybacking great inve...

12.04.08 | 10:36 AM
Latest News in Activist Investing

Since most hedge funds get paid based on their returns for the year, managers who want to get the most out of a stock investment often turn to shareholder activism as a way...

12.03.08 | 17:46 PM
more articles
cramer for sec chair
12.04.08 | 18:58 PM From author valuemac
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZackAttack
Housing Market
12.04.08 | 17:39 PM From author MTnews
more forums
Q. Since we already know tomorrows ...
12.04.08 | 17:05 PM Asked by blitz373

A. No...its not priced into the market

IMO, A lot of the bad news is not
priced, but people like blitz373 keep
buying at these prices anyway. I want
sp500 topping at like 750. After we get
real, buyers can handle the ups and
downs.

today 's lists
Analyst Upgrades

Analyst Upgrades for Dec. 2, 2008. more

Small Cap Value Plays

Stocks with market capitalizations between $250 million and $1 billion with a P/E ratio less than or equal to 10 and a quick ratio of greater than or equal to 1.0. A quick ... more

TheStreet.com TV Videos - Nov. 24

These are some of the stocks mentioned today on TheStreet.com TV. Click the URL below each stock to watch the videos. more